Evaluación del gen HER-2 como biomarcador en tumor mamario canino: aproximación epidemiológica y bioquímica

dc.contributorRivera Páez, Fredy
dc.contributorVargas Hernández, Carlos
dc.creatorClavijo Maldonado, Alejandro
dc.date2021-07-29T21:23:38Z
dc.date2022-01-31
dc.date2021-07-29T21:23:38Z
dc.date2022-01-31
dc.date.accessioned2023-09-06T18:27:01Z
dc.date.available2023-09-06T18:27:01Z
dc.identifierhttps://repositorio.ucaldas.edu.co/handle/ucaldas/16937
dc.identifierUniversidad de Caldas
dc.identifierRepositorio institucional Universidad de Caldas
dc.identifierhttps://repositorio.ucaldas.edu.co
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8697536
dc.descriptionIlustraciones
dc.descriptionspa: Se describieron características epidemiológicas de tumores mamarios caninos (TMC) con énfasis en los factores de riesgo que propenden a la presentación de TMC; raza, predisposición genética, edad, historia reproductiva, influencia hormonal, dieta, masa corporal y características clínicas. Se desarrolló una descripción de la prevalencia del TMC en el Municipio de Manizales, Colombia, tomando como base los pacientes registrados en centros de atención veterinaria. Se realizó la identificación de los patrones de la expresión del gen HER-2 en hembras caninas con TMC, empleando suero sanguíneo mediante las técnicas de ensayo por inmunoabsorción ligado a enzima (ELISA) y espectroscopia infrarroja con Transformada de Fourier (FTIR). Para la detección de concentraciones de proteína HER-2/neu se emplearon los kit ELISA (canino y humano). La toma de espectros IR se realizó en modo absorbancia con rango de frecuencia de 400-4000 cm-1 y resolución de 4 cm-1. El análisis estadístico para la descripción de la prevalencia incluyó prueba de Pearson chi-cuadrado con corrección de Yates y prueba exacta de Fisher (p-value<0.05), riesgo relativo, razón de momios (IC95%) y análisis de supervivencia de Kaplan-Meier. Se elaboraron curvas ROC y la estimación de ABC (IC 95%) para la identificación del punto de corte de las concentraciones en suero sanguíneo de HER-2 usando la prueba de ELISA. El análisis de los picos de expresión IR se realizó mediante la estimación de ABC y ARBC. Las razas puras presentaron una prevalencia del 79,14% y en general, la edad de 9,3 años fue el pico de presentación de neoplasia mamaria. Adicionalmente, la dieta casera posee alta relación con la prevalencia de TMC. El patrón clínico de presentación de TMC afectó principalmente el par mamario inguinal y el índice Kaplan-Meier fue mayor para hembras intervenidas quirúrgicamente desde el diagnóstico que las que no fueron intervenidas. El punto de corte óptimo en la prueba ELISA canina fue ≥0.31 ng/ml, Sn de 71.4% (CI 95%: 41,9%-91,6%) y Sp 67% (CI 95%: 22,3%-95,7%). Las AUC para ELISA canina y humana fueron 0,75 y 0,45 respectivamente. Los espectros IR correspondientes a lípidos (1161 cm-1, 1452 cm-1, 2851 cm-1) son de relevancia para la identificación de expresión del gen HER-2. Los hallazgos del presente estudio permitieron discriminar los estados HER/neu+ y HER-2/neu-, así como las características bioquímicas ligadas a ambos estados.
dc.descriptioneng: We described the epidemiological characteristics of canine mammary tumors with a focus on the risk factors that promote the presentation of CMT, such as breed, genetic predisposition, age, reproductive history, hormonal influence, diet, body mass, and clinical characteristics. Based on this, we conducted a prevalence description of CMT in the municipality of Manizales, Colombia. The gene expression patterns of HER2 in blood serum collected from female dogs with CMT were determined using enzyme-linked inmunosorbent assay (ELISA) and Fourier-transform infrared spectroscopy (FTIR). The detection of HER2/neu protein levels was done using canine and human ELISA kits. Infrared (IR) spectroscopy was done in absorbance mode at a frequency range of 400-4000 cm-1 and resolution of 4 cm-1. The statistical analyses performed included Pearson’s chi-squared test with Yates’ correction and Fisher’s exact test (p-value<0.05), relative risk, odds ratio (IC95%), and Kaplan-Meier survival analysis. We created ROC curves and estimated the AUC (IC 95%) to identify the ELISA cut-off of HER2 serum levels. The IR analysis of expression peaks was based on the estimation of AUC and RAUC. Purebreds showed a disease prevalence of 79.14% and, in general, the peak of presentation of mammary neoplasia was found at 9.3 years old. Furthermore, a homemade diet was found highly associated with the prevalence of CMT. The clinical presentation of CMT mainly affected the inguinal mammary glands; furthermore, the Kaplan-Meier estimator was greater for females with surgical intervention since diagnosis than for non-intervened females. The optimal cut-off for the canine ELISA tests was ≥0.31 ng/mL with 71.4% sensitivity (CI 95%: 41.9%-91.6%) and 67% specificity (CI 95%: 22.3%-95.7%). AUC for the canine and human ELISA tests were 0.75 and 0.45, respectively. The IR spectra of lipids (1161 cm-1, 1452 cm-1, 2851 cm-1) are relevant to determine HER2 gene expression. The findings of this study allowed discriminating HER/neu+ and HER-2/neu- states, as well as the biochemical characteristics linked to both states.
dc.description1. CAPÍTULOINTRODUCTORIO / 2. Objetivos / 2.1 Objetivo general / 2.2 Objetivos específicos / 3. MATERIALES Y MÉTODOS / 3.1. Área de influencia del estudio / 3.2. Población objetivo y análisis epidemiológico / 3.3. Variables de estudio / 3.4. Pacientes y muestras / 3.5. Detección y medición de proteína HER-2 en suero sanguíneo / 3.5.1. Análisis de ELISA / 3.5.2. Análisis FT-IR / 3.6. Análisis de datos / 4. RESULTADOS / Capítulo 1. Canine mammary cancer: clinical implications with specific focus on the HER-2 gene / Capítulo 2. Canine mammary gland tumors: risk factors and their epidemiological influence in Manizales-Colombia / Capítulo 3. ELISA and FTIR: HER2 gene expression in blood serum of canines with mammary tumor / Consideraciones finales / Anexos / Referencias
dc.descriptionMaestría
dc.descriptionMagister en Ciencias Biológicas
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.languageeng
dc.languagespa
dc.publisherFacultad de Ciencias Exactas y Naturales
dc.publisherMaestría en Ciencias Biológicas
dc.relationAndrade, N.R. & Harris, L.N. 2002. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 3(2):125‐137.
dc.relationAndrulis, I.L., Bull, S.B., Blackstein, M.E., et al. 1998. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16(4):1340‐1349.
dc.relationAntuofermo, E., Miller, M.A., Pirino, S., Xie, J., Badve, S. & Mohammed, S.I. 2007. Spontaneous mammary intraepithelial lesions in dogs--a model of breast cancer. Cancer Epidemiol Biomarkers Prev 16(11):2247‐2256.
dc.relationAtitwa, S.C. 2018. How Many Dogs Are There In The World?" . WorldAtlas. Consultado on line: worldatlas.com/articles/how-many-dogs-are-there-in-the-world.html.
dc.relationCancer Tomorrow. WHO-GLOBOCAN. 2018. [Consultado on line] https://gco.iarc.fr. Accessed 04 August 2019.
dc.relationCervone, M., Gavazza, A., Zbriger, A., Mancianti, F., & Perrucci, S. 2019. Intestinal parasite infections in dogs affected by multicentric lymphoma and undergoing chemotherapy. Comparative Immunology, Microbiology and Infectious Diseases 63: 81-86.
dc.relationChase, B.A., Johnston, S.A., Legutki, J.B. 2012. Evaluation of biological sample preparation for immunosignature-based diagnostics. Clinical and vaccine immunology : CVI, 19(3), 352–358.
dc.relationClamp, A., Danson, S. & Clemons, M. 2003. Hormonal and genetic factors for breast cancer. Surg J R Coil Surg Edinb Irel 1(1): 23-31.
dc.relationGamboa, O., Buitrago, L.A., Lozano, T., Dieleman, S., Gamboa, C. et al. 2016. Costos directos de la atención del cáncer de mama en Colombia. Revista Colombiana de Cancerología 20(2): 52-60.
dc.relationGoldschmidt, M., Peña, L., Rasotto, R. & Zappulli, V. 2011. Classification and Grading of Canine Mammary Tumors. Vet Pathol 48(1):117-31.
dc.relationGurova, K.V., Kwek, S.S.S., Koman, I.E., Komarov, A.P., Kandel E., Nikiforov M.A. & Gudkov A.V. 2002. Apoptosis Inhibitor as a Suppressor of Tumor Progression: Expression of Bcl-2 Eliminates Selective Advantages for p53-Deficient Cells in the Tumor. Cancer Biology & Therapy 1: 39-44.
dc.relationHampe, J.F. Misdorp, . 1974. Tumours and dysplasias of the mammary gland. Bulletin of the orld Health Organization 50(1-2): 111-133
dc.relationHenry, C.J. & Higginbotham, M.L. 2010. Cancer management in small animal practice. Ed Saunders Elsevier, Missouri. [Consultado on line] http://www.smallanimaloncology.com/. Accessed 06 April 2016.
dc.relationHsu, Y., Severinghaus, L.L., Serpell, J.A. 2003. Dog Keeping in Taiwan: Its Contributionto the Problem of Free-Roaming Dogs. Journal of applied animal welfare science. 6(1): 1–23.
dc.relationHughes, J., Macdonald, D.W. 2013. A review of the interactions between free-roaming domestic dogs and wildlife. Biological Conservation. 157: 341-335.
dc.relationKreunin, P., Yoo, C., Urquidi, V., Lubman, D.M., Goodison, S. 2007. Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics 7(2): 299-312.
dc.relationLippi, G., Blanckaert, N., Bonini, P., Green, S., Kitchen, S., Palicka, V., Vassault, A.J. Plebani, M. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med 46 (6): 764–772.
dc.relationMassei, G., Miller, L. 2013. A review of the interactions between free-roaming domestic dogs and wildlife. Theriogenology 80: 829-838.
dc.relationMotulsky, H.J. 2016. GraphPad Prism v.8.2.0 [programa de computación] https://www.graphpad.com. Accessed 17 August 2019.
dc.relationMurray, R.K., 2005. Cáncer, oncogénes y factores de crecimiento. En: Harper bioquímica ilustrada. Murray, R.K., Granner, D.K., Mayes, P.A., Rodwell, V.W (eds). Ed Manual Moderno, Bogotá, Colombia. pág. 887-911.
dc.relationOwen, L.N. 19 0. orld Health Organization. Veterinary Public Health Unit HO Collaborating Center for Comparative Oncology. TNM Classification of Tumours in Domestic Animals/ edited by L.N. Owen. World Health Organization. p. 16-20-
dc.relationPatsikas, M.N., Dessiris, A. 1996. The Lymph Drainage of the Mammary Glands in the Bitch: a Lymphographic Study. Part I: The lst, 2nd, 4th and 5th Mammary Glands. Anat. Histol. Ernbryol 25: 131-138.
dc.relationPatsikas, M.N., Dessiris, A. 1996. The Lymph Drainage of the Mammary Glands in the Bitch: a Lymphographic Study. Part II: the 3rd Mammary Gland. Gnat. Histol. Embryol 25: 139-143.
dc.relationPatsikas, M.N., Karayannopoulou, M., Kaldrymidoy, E., Papazoglou, L.G., Papadopoulou, P.L. et al. 2006. The Lymph Drainage of the Neoplastic Mammary Glands in the Bitch: A Lymphographic Study. Anat. Histol. Embryol 35: 228–234.
dc.relationRungsipipat, A., Tateyama, S., Yamaguchi, R., Uchida, K., Miyoshi, N. & Hayashi, T. 1999. Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. J Vet Med Sci 61(1):27‐32.
dc.relationSangha, S., Singh, A., Gupta, K., Sood, N.K. & Mohindroo, J. 2012. Factors Associated with Occurrence of Canine Mammary Tumours. Indian Vet. J 89(9): 29 – 31.
dc.relationSavino, M., Parrella, P., Copetti, M. et al. 2009. Comparison between real-time quantitative PCR detection of HER2 mRNA copy number in peripheral blood and ELISA of serum HER2 protein for determining HER2 status in breast cancer patients. Cell Oncol 31(3):203‐211.
dc.relationScarff, R.W., Torloni, H. 1968. Histological typing of breast tumors., International histological classification of tumours. World Health Organization, Geneva, 2(2): 13-20.
dc.relationŠoštarić-Zuckermann, I.C., Krešimir, S.K, Hohšteter, M., Artuković B., Beck A. et al. 2013. Incidence and types of canine tumours in Croatia. Veterinarski Arhiv 83(1): 31-45
dc.relationStewart BW, Wild CP, editors (2014). World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer.
dc.relationWHO. 2006. World health statistics 06. World Health Organizarion. Geneva, Switzerland. pp. 80.
dc.relationWHO. 2008. World health statistics. World Health Organizarion. Geneva, Switzerland. pp. 112.
dc.relationWHO. 2012. World health statistics. World Health Organizarion. Geneva, Switzerland. pp. 180.
dc.relationWHO. 2015. From MDGs Millenium Development Goals to SDGs Sustaniable Development Goals. World Health Organizarion. Geneva, Switzerland. pp. 216.
dc.relationWHO. 2016. World health statistics. Monitoring health for the SDGs Sustaniable Development Goals. World Health Organizarion. Geneva, Switzerland. pp. 136.
dc.relationWHO. 2017. World health statistics. Monitoring health for the SDGs Sustaniable Development Goals. World Health Organizarion. Geneva, Switzerland. pp. 116.
dc.relationWHO. 2018. World health statistics. Monitoring health for the SDGs Sustaniable Development Goals. World Health Organizarion. Geneva, Switzerland. pp. 100.
dc.relationWHO-GLOBOCAN. 2018. All cancers. Consultado on line: https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectErbB2
dc.subjectEspectro infrarrojo
dc.subjectInmunoabsorción
dc.subjectOncoproteína
dc.subjectNeoplasia mamaria
dc.subjectZoología
dc.subjectEnfermedad animal
dc.titleEvaluación del gen HER-2 como biomarcador en tumor mamario canino: aproximación epidemiológica y bioquímica
dc.typeTrabajo de grado - Maestría
dc.typehttp://purl.org/coar/resource_type/c_bdcc
dc.typeText
dc.typeinfo:eu-repo/semantics/masterThesis
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución